Savara Inc
NASDAQ:SVRA
Savara Inc
Total Equity
Savara Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Total Equity
$171.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$3.3B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$19.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$5.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-14%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$16.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
22%
|
CAGR 10-Years
31%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$29.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
21%
|
CAGR 10-Years
28%
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Total Equity?
Total Equity
171.4m
USD
Based on the financial report for Dec 31, 2024, Savara Inc's Total Equity amounts to 171.4m USD.
What is Savara Inc's Total Equity growth rate?
Total Equity CAGR 10Y
11%
Over the last year, the Total Equity growth was 22%. The average annual Total Equity growth rates for Savara Inc have been 6% over the past three years , 11% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet